healthcare AI - Page 19
Stories from healthcare AI come first, newest first, then stories from connected topics (Healthcare, AI Science & Health, Hub: Tech for Good, AI for science, AI, drug discovery), each labelled with where it comes from. This view is not indexed by search engines.
Latest
Anthropic Says Claude Designed Binders Against Scorpion Neurotoxins
Anthropic says Claude designed protein binders against scorpion neurotoxins, with 17 of 211 tested designs meeting its criteria. It claims no antivenom.
Ukraine Says a Heavy Drone Flew a Wounded Soldier to Safety, Claiming a First
Ukrainian units and Gurzuf Defence say a heavy drone winched a wounded soldier off the front line, a claimed first. The maker calls it a last resort.
Lilly Taps Metis TechBio’s AI to Steer Medicines to Target Tissues
Metis TechBio will use AI to design tissue-targeted drug carriers for Eli Lilly. Upfront cash is low double-digit millions; milestones run up to $1.1bn.
Scripps Research Gets Over 14 Million GPU Hours From Huang Foundation
Scripps Research gets more than 14 million GPU hours from the Huang Foundation via CoreWeave/NVIDIA. In-kind; no dollar value.
Google Research Runs AI Agents on Wet-Lab Robots in Closed Loops
Google Research: VERID digital twin on PyLabRobot, closed-loop aptamers, nanomolar FAP binders. Authors’ self-published results, not peer-reviewed.
CERN and Mistral Sign Intent to Build a Large Physics Model
CERN and Mistral signed a statement of intent to develop a Large Physics Model for collider physics. The model is not built yet; no timeline disclosed.
OpenAI Introduces the Rosalind Academic Plan for US University Labs
OpenAI’s Rosalind Academic Plan offers eligible US university labs up to 30 free seats for 12 months; GPT-Rosalind needs trusted-access approval.
Google DeepMind Shows Its Antigravity Agent Finding a New Antimicrobial Peptide Candidate, Which Still Needs Lab Testing
Google DeepMind says its Antigravity agent helped find a new antimicrobial peptide candidate. It is a computational lead now in lab testing.
Sanofi Options First Development Candidate From Its Recursion AI Collaboration
Sanofi has optioned a potential first-in-class oral immunology candidate from Recursion, triggering a $10m milestone. Phase 1 is planned for 2027.
insitro and AstraZeneca Sign AI Collaboration to Hunt Drugs for MASH and Cardiomyopathies
insitro gets $40m upfront and is eligible for up to about $1.46bn in potential milestones in an AstraZeneca AI deal for MASH and heart disease.
Latest on TSN
Explore the TSN Atlas: Every topic we cover, mapped. Click a bubble to dive in.